argenx SEARGX

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Netherlands · argenx.com

argenx SE is a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with academic researchers through its Immunology Innovation Program, argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker — VYVGART / VYVGART Hytrulo (efgartigimod) — and is evaluating its potential across multiple serious autoimmune diseases. Dual-listed on Euronext and Nasdaq.

Key ratios

Operating cash flow growth

141.2%TTM

EPS growth

39.8%TTM

2025 53.1%

FCF / Sales

18.2%TTM

2025 16.0%2024 -3.8%2023 -33.2%

Net margin

32.3%TTM

2025 30.5%2024 37.1%2023 -23.3%

ROA

11.6%TTM

2025 8.9%2024 -0.2%2023 -6.9%

ROE

23.6%TTM

2025 20.2%2024 17.4%2023 -8.5%

Revenue growth

70.3%TTM

2025 88.4%2024 77.2%2023 187.7%

Recent news

argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors 2026-09-17 · GlobeNewswire argenx Completes Acquisition of Forte Biosciences, Inc. 2026-08-27 · GlobeNewswire argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis 2026-08-17 · GlobeNewswire

Track ARGX in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer